Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhen NICE recommended semaglutide for weight management, it set clear expectations: clinical assessment, a supervised titration schedule, and ongoing review. Any provider offering semaglutide in the UK is legally required to meet those standards — the medicine is prescription-only and a qualified prescriber must be satisfied it is right for you before treatment begins. This page explains what that looks like in practice, how NHS and private routes differ, and what separates a safe, regulated provider from one that cuts corners.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
NICE's appraisal of semaglutide for weight management (TA875) does not just recommend the medicine, it specifies the conditions under which it should be used. Adults must have a BMI of 35 or above (or 30 to 34.9 if they meet certain referral criteria), at least one weight-related comorbidity, and must be managed within a service that provides dietary guidance, physical activity support, and behavioural input alongside the medicine. Treatment is limited to two years, and if a patient has not lost at least 5% of their body weight after six months on the maintenance dose, continuing is reviewed. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. These are not suggestions, they are the clinical framework that a responsible provider builds around. If you are looking to buy semaglutide through a private route, a consultation that consists of ticking a box and handing over a pen falls short of what the evidence-base, and regulators, expect. When you are assessing any provider, ask what clinical oversight looks like after your first injection, not just before it.
On the NHS, semaglutide is available through specialist weight management services under TA875. Waiting lists are often long, the eligibility bar is high, and the multidisciplinary support built in is genuine. For many people, that route is simply not accessible, either they do not qualify, or the wait is measured in years rather than weeks. Private providers fill that gap, legally, as long as they operate through a GPhC-registered pharmacy and employ a prescriber who takes full clinical responsibility for each decision. A prescriber (a real clinician, not software) reads your consultation, checks your medical history, and decides whether semaglutide is appropriate for you. At nume, that review happens the same day you submit your answers. There are no algorithms making prescribing decisions. If you want to compare how private providers structure access, our guide to Wegovy providers breaks that down specifically. The honest difference between NHS and private is not quality of medicine; it is speed and access, traded against the wraparound support the NHS builds in as standard.
The MHRA has been direct about this. Since counterfeit Ozempic and Saxenda pens first appeared in 2023, enforcement has escalated substantially, culminating in the first UK raid on an illicit manufacturing site producing counterfeit tirzepatide pens, in Northampton in October 2025. Fake pens have contained insulin. The consequences of injecting an unknown substance sold as a GLP-1 medicine can be severe. Providers to avoid include anyone offering semaglutide without a prior prescription and clinical assessment; sellers found only on social media, WhatsApp or marketplace platforms; listings priced far below the known UK market range; and any seller that promises same-day dispatch without asking a single medical question. You can report a suspect seller directly at yellowcard.mhra.gov.uk, the MHRA acts on these reports. One practical check that takes two minutes: search the provider on the GPhC register. If the pharmacy does not appear, the supply chain has no regulatory oversight and the medicine's provenance is unknown. If you have come across services claiming to let you buy Wegovy online with no consultation, that is itself a red flag worth understanding before you go any further. For more on what to look for in a private provider, this page on choosing a Wegovy provider covers the specific questions worth asking.
Something our prescribers hear fairly regularly: people choosing a provider based on whoever's cheapest when they last checked, around payday, or after a bank holiday when they've had a few days to think. Price is a reasonable starting point, but for a prescription medicine it is the wrong finishing line. Eli Lilly raised Mounjaro's UK list price substantially from September 2025, and typical private semaglutide prices across providers range widely depending on dose, what is included, and how the service is structured. A headline price that excludes consultation fees, prescription charges, delivery, and aftercare access will look cheaper until you add those up. Our breakdown of Wegovy costs covers what a transparent price should reasonably include. At nume, one price covers the consultation, prescription, tracked next-working-day delivery, and 7-day aftercare, no subscription, no auto-renewal, and a prescriber reviews every repeat order before anything is sent. If you would like to find out what regulated in-person and online options are available to you, our page on Wegovy providers near me is a useful place to start alongside the weight-loss treatment overview. If you would like to understand the broader treatment options alongside semaglutide, the weight-loss treatment overview is a practical starting point before your consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.